扶正养营汤治疗慢性再生障碍性贫血的临床研究

Clinical Study of Fuzheng Yangying Decoction on Chronic Aplastic Anemia

目的观察扶正养营汤治疗慢性再生障碍性贫血的临床疗效。方法将60例慢性再生障碍性贫血患者随机分为3组,每组各20例。分别予扶正养营汤、环孢素A、环孢素A+扶正养营汤,疗程3个月,观察各组临床疗效及骨髓上清IL-12水平变化。结果环孢素A+扶正养营汤组临床疗效优于扶正养营汤及环孢素A组(P<0.05);扶正养营汤组与环孢素A组临床疗效相比差异无统计学意义(P>0.05)。各组治疗后骨髓上清IL-12水平均有不同程度下降,差异有统计学意义(P<0.05);环孢素A组下降幅度大于扶正养营汤组(P<0.05);环孢素A组与环孢素A+扶正养营汤组相比下降幅度差异无统计学意义(P>0.05)。结论扶正养营汤能降低慢性再生障碍性贫血患者骨髓上清IL-12水平,有较好的临床疗效且无不良反应,值得临床推广应用。

Objective To observe the therapeutic effect of Fuzheng Yangying decoction on patients with chronic aplastic anemia. Methods The 60 patients with chronic aplastic anemia were divided into 3 groups as the traditional Chinese medicine group （TCM group, n=20） with Fuzheng Yangying decoction, the western medicine group （WM group, n=20） with the cyclosporin A and the integrated Chinese and western medicine （TWM group, n=20） with Fuzheng Yangying decoction added cyclospofin A. All the groups were treated for 3 months. The clinical therapeutic effect and the level of interleukin-12 of the supernatant in bone marrow were assessed. Results The therapeutic effect in TWM group was better significantly than that in CTM group and WM group （P〈0.05）, in which there were no significant differences between them （P〉0.05）. Compared with the level of interleukin-12 of the supernatant in bone marrow before the treatment, the level of interleukin -12 in all three groups were decreased ＇after the treatment; the differences were statistically significant（P〈0.05）. The g rearer decrease in the level of interleukin-12 was exhibited in the WM group than that in CTM group （P〈0.05）. There were no significant differences between WM and TWM groups in the decrease in the level of interleukin-12（P〉0.05）. Conclusion Fuzheng Yangying decoction can decrease the level of interleukin-12 of the supernatant in bone marrow for the patients with chronic aplastic anemia, has good therapeutic effect for the disease without any side-effect and is worth to be used in clinic.